These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35697571)

  • 1. Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
    Rollier CS; Dold C; Blackwell L; Linder A; Silva-Reyes L; Clutterbuck E; Davis K; Ford K; Liu X; Holland A; Chan H; Harbinson H; O'Connor D; Borrow R; Snape MD; Pollard AJ
    Vaccine; 2022 Jul; 40(32):4453-4463. PubMed ID: 35697571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study.
    Davis K; Ford K; Craik R; Galal U; Rollier CS; Pollard AJ
    Trials; 2019 Jul; 20(1):455. PubMed ID: 31340842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
    Nolan T; Santolaya ME; de Looze F; Marshall H; Richmond P; Henein S; Rheault P; Heaton K; Perrett KP; Garfield H; Gupta A; Ferguson M; D'Agostino D; Toneatto D; O'Ryan M
    Vaccine; 2019 Feb; 37(9):1209-1218. PubMed ID: 30691980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
    Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ
    CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
    Iro MA; Snape MD; Voysey M; Jawad S; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Dull P; Pollard AJ;
    Vaccine; 2017 Jan; 35(2):395-402. PubMed ID: 27914744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.
    Vesikari T; Brzostek J; Ahonen A; Paassilta M; Majda-Stanislawska E; Szenborn L; Virta M; Clifford R; Jackowska T; Kimmel M; Bindi I; Keshavan P; Pedotti P; Toneatto D
    Hum Vaccin Immunother; 2021 Nov; 17(11):4689-4700. PubMed ID: 34582323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial.
    Martinón-Torres F; Carmona Martinez A; Simkó R; Infante Marquez P; Arimany JL; Gimenez-Sanchez F; Couceiro Gianzo JA; Kovács É; Rojo P; Wang H; Bhusal C; Toneatto D
    J Infect; 2018 Mar; 76(3):258-269. PubMed ID: 29253560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
    Sadarangani M; Sell T; Iro MA; Snape MD; Voysey M; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Pollard AJ;
    CMAJ; 2017 Oct; 189(41):E1276-E1285. PubMed ID: 29038320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
    Snape MD; Philip J; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Kittel C; Toneatto D; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2013 Oct; 32(10):1116-21. PubMed ID: 23958808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.
    Vesikari T; Prymula R; Merrall E; Kohl I; Toneatto D; Dull PM
    Vaccine; 2015 Jul; 33(32):3850-8. PubMed ID: 26141011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.
    Martinón-Torres F; Nolan T; Toneatto D; Banzhoff A
    Hum Vaccin Immunother; 2019; 15(12):2940-2951. PubMed ID: 31246520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.